1 / 3

Epilepsy Drug Market

The global epilepsy drug market size is projected to register a substantial CAGR during the forecast period, 2021-2018. The growth of the market is attributed to the anticipated launch of epilepsy drugs that are currently in the pipeline. The growth of the market is also attributed to the global increasing incidence of epilepsy cases along with the rising demand for third-generation anti-epileptics.

Download Presentation

Epilepsy Drug Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Epilepsy Drug Market - Global Industry Analysis, Size, Share, Growth , Trends, and Forecast The global epilepsy drug market size is projected to register a substantial CAGR during the forecast period, 2021-2018. The growth of the market is attributed to the anticipated launch of epilepsy drugs that are currently in the pipeline. The growth of the market is also attributed to the global increasing incidence of epilepsy cases along with the rising demand for third-generation anti-epileptics. Epilepsy is one of the most common disorders in which the brain’s nerve cell activity gets disturbed and causes seizures. Epilepsy is expected to occur when an individual acquires some brain injury such as stroke or trauma. It can also occur due to some genetic disorder. When an individual suffers from epilepsy their brain activity becomes abnormal which leads to loss of awareness, sensations, and behaving unusually. Epilepsy cannot be cured but can be controlled with the usage of drugs. Change in diet, devices, and surgery are also done in some cases to treat epilepsy. As per the reports by the Epilepsy Foundation of America, there are 65 million individuals are suffering from epilepsy across the globe among which the U.S, alone have 3.4 million individuals who develop epilepsy at some point in their life. Every year 150,000 new cases are registered in the U.S. Request Sample link :-https://growthmarketreports.com/request-sample/2448 Market Trends, Drivers, Restraints, and Opportunities  Increasing approvals of new drugs for the treatment of epilepsy in the past few years is a key factor driving the market growth expansion during the forecast period. Availability of healthcare infrastructure in the developed region is another factor helping the market growth in the coming years. 

  2. Side effects caused due to the consumption of epilepsy drugs are estimated to act as a restraining factor that can hinder the market growth. Recent expiration of patents of drugs by major brands is a key challenge that can hamper the market growth during the forecast period. Rising initiatives to increase awareness of the disorder and rising number of people who are aware of early diagnostic of the disorder across the globe present key opportunities for the market expansion.   Market Segment Insights: Third generation anti-epileptics segment is anticipated to witness a rapid growth On the basis of treatments, the global epilepsy drug market is divided into first generation anti- epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third generation anti-epileptics segment is anticipated to witness a rapid growth during the forecast period attributed to the rising availability of these drugs and their deep penetration in the market. The third generation anti- epileptics include drugs such as lacosamide, eslicarbazepine, and retigabine. The first generation anti- epileptics include drugs such as carbamazepine, phenobarbital, valproate, primidone, and ethosuximide. Among these, carbamazepine is the most common drug prescribes by professionals for the treatment of partial and generalized seizures. These are key factors likely to boost the segment growth of the first generation. Meanwhile, the second generation anti-epileptics consist of drugs such as brivaracetam, perampanel, levetiracetam, and lamotrigine. Enquiry Link :-https://growthmarketreports.com/enquiry-before-buying/2448 Competitive Landscape Key players competing in the global epilepsy drug market are Sanofi S.A; Cephalon, Inc.; Johnson & Johnson; Pfizer, Inc.; Eisai Co., Ltd.; Valeant Pharmaceuticals International, Inc.; Novartis AG; GlaxoSmithKline PLC.; Abbott Laboratories, Inc.; Sunovion Pharmaceuticals, Inc.; and UCB Pharma Ltd. Many of these players have adopted business strategies such as the development of novel drugs, launching of new products, advancement of technologies, partnerships, mergers, and production capacity expansion in order to increase their expansion, their consumer base, and market position globally. About Growth Market Reports: GMR provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. GMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys. Contact:

  3. Growth Market Reports Phone: +1 909 414 1393 Email: sales@growthmarketreports.com Web: https://growthmarketreports.com Follow Us: LinkedIn | Twitter

More Related